GlassScriptPhysician profile
Lauren S Chiec
NPI 1932594728
$6,485.45
in general payments reported to CMS, 2019-2025
14 companies · $5,922 in 2025
The $5,922 reported for 2025 was more than what 75% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2023: $20.09 · 2024: $428 · 2025: $5,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,698 · Food and Beverage: $655 · Education: $17.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,697.50 |
| Food and Beverage | $655.11 |
| Education | $17.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $2,561.53 | 2024-2025 | Alunbrig |
| E.R. Squibb & Sons, L.L.C. | $2,024.20 | 2024-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $1,336.98 | 2024-2025 | Rybrevant |
| Bayer Healthcare Pharmaceuticals INC. | $138.09 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $123.41 | 2024-2025 | Imfinzi |
| Merck Sharp & Dohme LLC | $115.74 | 2024-2025 | Keytruda, Welireg |
| Eisai INC. | $90.16 | 2023-2025 | |
| Tempus Ai, INC | $29.53 | 2024 | |
| Novartis Pharmaceuticals Corporation | $27.41 | 2025 | |
| Astellas Pharma US INC | $22.17 | 2024 | Padcev |
| Array Biopharma INC | $16.23 | 2024 | Lorbrena, Braftovi, Xalkori |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Chiec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.